[Anaphylactoid reaction during administration of tissue plasminogen activator (t-PA)].
The use of tissue plasminogen activator (t-PA) in the management of acute myocardial infarction, as effective thrombolytic agent, is well established. Thrombolytic therapy, limiting the extent of myocardial necrosis, reduces the infarct-related morbidity and mortality and improves the prognosis in patients with acute myocardial infarction. Thrombolytic agents present various side effects. Allergic reactions may occur with both streptokinase (ST) (or with anistreplase, the equimolecular mixture of streptokinase and human plasminogen); and t-PA. The incidence of allergic reactions associated with the use of t-PA is much lower if compared with other thrombolytic agents. Since t-PA is structurally identical to endogenous t-PA, its administration should not cause anaphylactic reactions. The purpose of this case presentation is to describe the occurrence of an anaphylactoid reaction during infusion of t-PA in a 63 year-old man, admitted to the Cardiac Care Unit (C.C.U.) with diagnosis of acute myocardial infarction.
Cannas
S
S
Cattedra di Cardiologia, Università degli Studi, Padova.
De Leo
A
A
Marzari
A
A
D000208:Acute Disease; D000707:Anaphylaxis / Q000503:physiopathology*; D004562:Electrocardiography; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D010960:Plasminogen Activators / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D010959:Tissue Plasminogen Activator / Q000009:adverse effects* / Q000627:therapeutic use
D011994:Recombinant Proteins; D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator
Reazione anafilattoide durante somministrazione di attivatore tissutale del plasminogeno (t-PA).